AstraZeneca stock: RBC keeps GBp 14,500 target for AstraZeneca stock

Published on 10/16/2026 at 17:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 30, 2026. AstraZeneca stock costs EUR 147.90 on October 16, 2026 at Lang & Schwarz, LSE shares fell 2.11 percent.

Analyst target and reporting date

RBC Capital Markets kept its Outperform rating and GBp 14,500 target on October 15, 2026.
AstraZeneca scheduled its third-quarter results for October 30, 2026.
AstraZeneca stock costs EUR 147.90 at Lang & Schwarz on October 16, 2026 at 5:37 p.m. CEST.
The stock trades at a price-to-earnings ratio of 24.82, with a market capitalization of GBP 192.8 billion.

Aquarell einer Cambridge-artigen Flusslandschaft mit Forschungsgebäuden — AstraZeneca plc (ISIN GB0009895292) unterhält einen bedeutenden Forschungsstandort in der britischen Universitätsstadt Cambridge, Illustration mit AI erstellt.

RBC Capital Markets kept its Outperform rating and GBp 14,500 price target for AstraZeneca on October 15, 2026, leaving the target 16.65 percent above the LSE price of GBp 12,430. Yahoo Finance reported that RBC expects a quiet third quarter before the company's scheduled results.

Results arrive October 30

AstraZeneca's investor-relations calendar lists its 9M and third-quarter 2026 results for October 30, 2026. The same calendar also lists an ESMO management event for October 26, 2026, giving investors two dated milestones before the results release. AstraZeneca identifies both dates on its investor-relations page.

Price position and trading range

At Lang & Schwarz, AstraZeneca stock stood at EUR 147.90 on October 16, 2026 at 5:37 p.m. CEST, during after-hours trading. The bid was EUR 147.55 and the ask was EUR 148.25. On the LSE, AstraZeneca last stood at GBp 12,430 at 3:29 p.m. UTC, down 2.11 percent from the prior close of GBp 12,698. The LSE session range was GBp 12,418 to GBp 12,576, while the 52-week range was GBp 9,892 to GBp 15,732.

Valuation before the results

AstraZeneca's market capitalization was GBP 192.8 billion, and its price-to-earnings ratio was 24.82 on October 16, 2026. The trailing dividend yield was 0.02 percent. The LSE quote showed volume of 1,682,009 shares against an average volume of 3,373,549 shares.

Comparison with peers

AstraZeneca (LSE, GBp): minus 2.11 percent, P/E 24.82, market capitalization GBP 192.8 billion.

GSK (LSE, GBp): minus 0.64 percent, P/E 15.60, market capitalization GBP 74.4 billion.

For investors, the key distinction is timing. RBC's target provides a dated valuation reference, while the October 30 results will supply the next fundamental test for the pipeline and earnings outlook. AstraZeneca's October 26 management event comes four days earlier.

Trading level and upcoming dates

The euro quotation sits between the two recent German-market prices visible in the trading record, while the LSE price remains below its 52-week high by 20.97 percent. The next scheduled company date is the ESMO management event on October 26, followed by the 9M and third-quarter results on October 30. AstraZeneca stock was trading at EUR 147.90 at Lang & Schwarz on October 16, 2026 at 5:37 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.